When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Hairy cell leukemia

ბოლო მიმოხილვა: 14 Oct 2025
ბოლო განახლება: 25 Oct 2024

შეჯამება

განსაზღვრება

ანამნეზი და გასინჯვა

ძირითადი დიაგნოსტიკური ფაქტორები

  • abdominal fullness or discomfort
  • splenomegaly
სრული ტექსტი

სხვა დიაგნოსტიკური ფაქტორები

  • weakness and fatigue
  • unexplained weight loss
  • bruising and bleeding
  • pallor
  • recurrent infections
  • hepatomegaly
  • lymphadenopathy
  • neurologic findings
  • associated systemic immunologic disorders
სრული ტექსტი

რისკფაქტორები

  • middle age
  • male sex
  • white ancestry
  • western hemisphere location
  • environmental exposures
  • genetic predisposition
  • Epstein-Barr virus
  • infectious mononucleosis
სრული ტექსტი

დიაგნოსტიკური კვლევები

1-ად შესაკვეთი გამოკვლევები

  • CBC with differential
  • peripheral blood smear
  • bone marrow trephine biopsy and aspiration (morphology assessment)
  • immunophenotyping (immunohistochemistry or flow cytometry)
  • comprehensive metabolic panel
  • serum lactate dehydrogenase (LDH)
  • viral serology for hepatitis B and C
სრული ტექსტი

გასათვალისწინებელი კვლევები

  • molecular analysis (for BRAF V600E mutation or IGHV4-34 rearrangement)
  • CT chest, abdomen, and pelvis
სრული ტექსტი

მკურნალობის ალგორითმი

მწვავე

no indication(s) for treatment

indication(s) for treatment present: without splenic rupture or massive splenomegaly or marked thrombocytopenia precluding chemotherapy

indication(s) for treatment present: with massive symptomatic splenomegaly or splenic rupture or marked thrombocytopenia precluding chemotherapy

მიმდინარე

early relapse (<2 years) or refractory disease

late relapse (≥2 years)

კონტრიბუტორები

ავტორები

Ambuj Kumar, MD, MPH

Professor

USF Health Office of Research

Department of Internal Medicine, College of Medicine

Moffitt Cancer Center & Research Institute, Department of Health Outcomes & Behavior

University of South Florida

Tampa

FL

გაფრთხილება:

AK declares that he has no competing interests.

Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

Professor

Division of Hematology-Oncology

Blood and Marrow Transplantation Program

Mayo Clinic

Jacksonville

FL

利益声明

MKD declares that he has no competing interests.

鸣谢

Dr Ambuj Kumar and Dr Mohamed Kharfan-Dabaja would like to gratefully acknowledge Dr Benjamin Djulbegovic, a previous contributor to this topic.

利益声明

BD declares that he has no competing interests.

同行评议者

Daniel Catovsky, MD, FRCP, FRCPath, DSc, FMedSc

Consultant Haemato-Oncologist

Section of Haemato-Oncology

Brookes Lawley Institute of Cancer

Sutton

UK

利益声明

DC declares that he has no competing interests.

Roger Lyons, MD

Clinical Professor of Medicine

University of Texas Health Science Center San Antonio

San Antonio

TX

利益声明

RL declares that he has no competing interests.

Rebecca Connor, MD

Chief Fellow

Section of Hematology and Oncology

Department of Internal Medicine

Wake Forest University Baptist Medical Center

Winston-Salem

NC

利益声明

RC declares that she has no competing interests.

Claire Dearden, BSc, MD, FRCP, FRCPath

Consultant Haematologist

The Royal Marsden Hospital

Sutton

Surrey

UK

利益声明

CD declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

参考文献

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

关键文献

Parry-Jones N, Joshi A, Forconi F, et al. Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol. 2020 Dec;191(5):730-7.全文  摘要

Troussard X, Maître E, Paillassa J. Hairy cell leukemia 2024: update on diagnosis, risk-stratification, and treatment - annual updates in hematological malignancies. Am J Hematol. 2024 Apr;99(4):679-96.全文  摘要

Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017 Feb 2;129(5):553-60.全文  摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hairy cell leukemia [internet publication].全文

Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v100-7.全文  摘要

参考文献

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Hairy cell leukemia images
  • 鉴别诊断

    • Chronic lymphocytic leukemia (CLL)
    • Mantle cell lymphoma
    • Prolymphocytic leukemia
    更多 鉴别诊断
  • 指南

    • NCCN clinical practice guidelines in oncology: hairy cell leukemia
    • Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V)
    更多 指南
  • padlock-locked登录或订阅即可浏览 BMJ Best Practice 临床实践完整内容

内容使用需遵循免责声明